Dear Colleagues,

Most patients have advanced tumors due to late diagnosis and, as a result, survival outcomes remain poor despite advances in treatment and decades of research. To date, oncology has led precision medicine efforts, largely because of our broad understanding of the role of genetic mutations in cancer development and progression. Recent advances in precision medicine techniques have led to unprecedented efforts. Precision cancer medicine depends on the impact of germline and somatic cell differences on the way cancer patients respond to treatment. Currently, precision cancer medicine is in the midst of a multi-omics revolution: improvements in measurement technologies have made it possible for the first time to sequence thousands of exomes/whole genomes, and even to explore entire genomes, transcriptomes, proteomes, and metabolites at the single-cell level. Molecular characterization will help clinicians to provide information relevant to personalized treatment planning through a multifaceted assessment of multi-omics. To realize the potential of therapeutics in clinical applications, it is essential to understand the fundamental aspects of cancer biology. In this special issue, we look to achieve precision in cancer medicine through a multi-omics approach. We encourage submissions that utilize a multi-omics approach to discover new findings or new targets in cancer. We encourage submissions that utilize a multi-omics approach to discover new cancer discoveries or new targets in order to effectively generate, analyze, and interpret multi-omics data to inform decisions based on precision medicine.

- Personalized medicine in oncology
- Cancer biomarkers: screening and diagnosis
- Multi-omics analysis
- Epidemiology

Dr. Chia-Jung Li and Dr. Zhenjian Zhuo

Guest Editors